---
title: "UNH’s 86.7% MCR had an $860M asterisk — plus Axon and Gartner still live Aug 4"
description: "If you took UnitedHealth’s 86.7% medical care ratio at face value, the filing adds a catch: $860M of net favorable prior-period development helped it. Axon reports off Q1 $807M (+34%, ninth straight 30%+ quarter); Gartner off contract value $5.3B but revenue down 1.5%. Research, not tips."
canonical: https://evidinvest.com/blog/aug4-2026-healthcare-adjacent-earnings-unh-axon-it-2026-08-03
date: "2026-08-03"
last_updated: "2026-08-03"
author: "EvidInvest Team"
publisher: "EBD Sweden AB (EvidInvest)"
tags: ["UNH", "AXON", "IT", "UnitedHealth", "Axon", "Gartner", "healthcare", "earnings preview", "SEC filings"]
---

# UNH’s 86.7% MCR had an $860M asterisk — plus Axon and Gartner still live Aug 4

- Published: 2026-08-03
- Author: EvidInvest Team, EvidInvest (published by EBD Sweden AB)
- Canonical URL: https://evidinvest.com/blog/aug4-2026-healthcare-adjacent-earnings-unh-axon-it-2026-08-03
- Research, not investment advice.

> If you took UnitedHealth’s 86.7% medical care ratio at face value, the filing adds a catch: $860M of net favorable prior-period development helped it. Axon reports off Q1 $807M (+34%, ninth straight 30%+ quarter); Gartner off contract value $5.3B but revenue down 1.5%. Research, not tips.

Not everything on the August 4 tape is chips and racks — and not every clean
headline number survives contact with its own press release. The example this
week: [UnitedHealth](https://evidinvest.com/valuation/UNH)’s much-quoted 86.7%
medical care ratio came with **$860M of net favorable prior-period
development** attached, a footnote most recaps skipped. This checklist digests
[UNH](https://evidinvest.com/valuation/UNH) (**already reported** July 16) and previews
[Axon](https://evidinvest.com/valuation/AXON) and
[Gartner](https://evidinvest.com/valuation/IT), the adjacent names still live
in the window. [Royal Caribbean](https://evidinvest.com/valuation/RCL) printed July 28; noted only as calendar
spillover from the same ticker batch.

This is research, not investment advice — if you want tips, wrong page.
Figures from SEC Exhibit 99.1 filings.

## Who prints when

| Ticker | Status | Last filed checkpoint |
| --- | --- | --- |
| **[UNH](https://evidinvest.com/valuation/UNH)** | **Already** Jul 16 | Q2 Ex 99.1 — digest below |
| **[AXON](https://evidinvest.com/valuation/AXON)** | **~Aug 4** | Q1 Ex 99.1 (May 6) |
| **[IT](https://evidinvest.com/valuation/IT)** | **~Aug 4** | Q1 Ex 99.1 (May 5) |
| **[RCL](https://evidinvest.com/valuation/RCL)** | **Already** Jul 28 | Travel adjacent — skip for thesis |

## UnitedHealth — Q2 already on file (digest, not preview)

Q2 2026 Exhibit 99.1 (Jul 16; accession `0000731766-26-000191`, CIK
[0000731766](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000731766&type=8-K)):

| Line | Amount |
| --- | ---: |
| Revenue | **$112.0B** |
| Earnings from operations | **$8.0B** |
| EPS / adjusted EPS | **$6.04** / **$6.38** |
| Medical care ratio (MCR) | **86.7%** (vs 89.4% YoY) |
| UHC people served | **48.5M** (**−525k** sequential) |
| UHC revenue / op. earnings | **$86.0B** / **$3.9B** (op. margin **4.6%**) |
| Optum revenue / earnings | **$65.7B** / **$4.0B** (+**160 bps** margin YoY) |
| **FY26 diluted EPS outlook** | **$18.45–$18.95** |
| **FY26 adjusted EPS outlook** | **$19.50–$20.00** |
| FY26 MCR outlook | **88.1% ± 25 bps** |

The asterisk on the headline: the 86.7% MCR was **affected by $860M of net
favorable prior-period reserve development**, the majority of it related to
2026 dates of service. Strip the framing and the read changes — a chunk of the
270-bp YoY MCR improvement is reserve trueup, not purely underlying cost trend.
That is exactly why the company still guides FY26 MCR to **88.1% ± 25 bps**,
well above the Q2 print.

Optum Health detail worth keeping: Q2 revenue **$23.5B** (−5% YoY) on ~**700k**
fewer value-based-care patients — progress on cost management with a membership
headwind.

**Residual watch (post-print):** underlying medical cost trend once the $860M
development washes out, Medicare Advantage / Medicaid mix, whether the raised
adj. EPS band holds into Q3, and Optum Insight AI product conversion after the
Alegeus close.

## Axon — Q1 baseline into the Aug 4 print

Q1 2026 Exhibit 99.1 (May 6; CIK
[0001069183](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001069183&type=8-K)):

| Line | Amount |
| --- | ---: |
| Revenue | **$807M** (+**34%** YoY) |
| Software & Services | **$355M** (+**35%**) |
| ARR | **$1.5B** (+**35%**) |
| NRR | **125%** |
| AI products | **+700%** YoY |
| Counter-drone | **+300%** YoY |
| FY revenue growth outlook (raised) | **30–32%** |
| Adj. EBITDA margin frame | **~25.5%** |

Q1 marked the **ninth consecutive quarter of 30%+ revenue growth** — the streak
is the thing Tuesday either extends to ten or breaks. Axon is public-safety /
software-adjacent, not hospital MCR — different risk set than UNH, same
“budget execution” tape.

**Aug 4 scorecard:** (1) reaffirm or raise the **30–32%** growth band, (2)
software mix vs. devices, (3) ARR / NRR 125% hold, (4) AI and counter-drone
still compounding off a small base, (5) FCF vs. growth spend.

## Gartner — enterprise spend proxy on the same day

Q1 2026 Exhibit 99.1 (May 5; accession `0000749251-26-000165`, CIK
[0000749251](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000749251&type=8-K)):

| Line | Amount |
| --- | ---: |
| Contract value | **$5.3B** (+**1.0%** YoY FX-neutral) |
| Revenues | **$1.511B** (**−1.5%** reported / **−4.3%** FX-neutral) |
| Adjusted EPS | **$3.32** |
| Share repurchases (quarter) | **$535M** |
| Buyback authorization | Board added **$600M** in April 2026 |

Read that table honestly: **revenue is shrinking** (−1.5% reported, −4.3%
FX-neutral) while adjusted EPS grows — the gap is buybacks and cost discipline,
not demand. Contract value barely positive at +1.0% FX-neutral is the
forward-demand tell for enterprise tech budgets (including healthcare IT).
Gartner is research & advisory, not a care-delivery name.

**Aug 4 scorecard:** contract value re-acceleration or continued stall;
whether revenue decline narrows; retention; H2 guide; Research vs. Conferences
mix; pace of the fresh $600M buyback authorization.

## Royal Caribbean — calendar only

[RCL](https://evidinvest.com/valuation/RCL) Q2 (Jul 28): revenue **$4.8B** (+6%); load factor **110%**; FY revenue
growth guide **~9%**. Travel, not healthcare — drop from this thesis.

## One scoreboard

1. **[UNH](https://evidinvest.com/valuation/UNH) (done)** — 86.7% MCR minus the $860M development, and the
   **$19.50–$20.00** adj. EPS band, are the real bars.
2. **[AXON](https://evidinvest.com/valuation/AXON) (live)** — extend the 30%+ streak to a tenth quarter with
   software/ARR quality.
3. **[IT](https://evidinvest.com/valuation/IT) (live)** — contract value as the enterprise-budget tell; watch whether
   EPS growth keeps outrunning shrinking revenue.
4. **Do not confuse** insurer underwriting ([UNH](https://evidinvest.com/valuation/UNH)) with public-safety software
   ([AXON](https://evidinvest.com/valuation/AXON)) or research wallets ([IT](https://evidinvest.com/valuation/IT)) — same week, different models.

Headlines quoted the MCR; the filing sized the reserve release. Live multiples:
[UNH](https://evidinvest.com/valuation/UNH) ·
[AXON](https://evidinvest.com/valuation/AXON) ·
[IT](https://evidinvest.com/valuation/IT) ·
[RCL](https://evidinvest.com/valuation/RCL).

## Primary sources

UNH Q2 Ex 99.1 (Jul 16):
https://www.sec.gov/Archives/edgar/data/731766/000073176626000191/
(`0000731766-26-000191`).

AXON Q1 Ex 99.1:
accession family May 6, 2026 (`axon-20260506xex991`), CIK 0001069183.

IT Q1 Ex 99.1:
https://www.sec.gov/Archives/edgar/data/749251/000074925126000165/
(`0000749251-26-000165`).

**First step:** open UNH’s Q2 release and find the prior-period development
sentence — one number, $860M, and you’ll read every MCR headline this quarter
differently.

Research, not investment advice.

---

Cite the canonical URL above (https://evidinvest.com/blog/aug4-2026-healthcare-adjacent-earnings-unh-axon-it-2026-08-03), not this Markdown file. Research, not investment advice.

## Sitemap

All posts in Markdown: https://evidinvest.com/blog/index.md · feeds: https://evidinvest.com/blog/rss.xml and https://evidinvest.com/blog/feed.json ·
the [index for language models](https://evidinvest.com/llms.txt) · the full [sitemap](https://evidinvest.com/sitemap.md).